Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in different types of cancer. However, the underlying mechanisms remain elusive. Here, combining detailed analysis of human tumour samples with preclinical tumour models, we report that concomitant blockade of CTLA-4 and PD-1 improves anti-tumour immune responses and synergistically eradicates tumour. Mechanistically, combination therapy relies on the interdependence between IL-7 and IFN-γ signalling in T cells, as lack of either pathway abrogates the immune-boosting and therapeutic effects of combination therapy. Combination treatment increases IL-7Rα expression on tumour-infiltrating T cells in an IFN-γ/IFN-γR signalling-dependent manner, which may serve as a potential biomarker for clinical trials with immune checkpoint blockade. Our data suggest that combining immune checkpoint blockade with IL-7 signalling could be an effective modality to improve immunotherapeutic efficacy. Taken together, we conclude that combination therapy potently reverses immunosuppression and eradicates tumours via an intricate interplay between IFN-γ/IFN-γR and IL-7/IL-7R pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [94]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 blocking therapy of tumor-bearing mice also reportedly improves IFN-ɤ signaling in T cells (94).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“On a side note, identification of biomarkers that can predict which patients respond to cancer immunotherapy is an active research area 45 .”
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“These findings, together with recent reports that blocking the PD-1/PD-L1 pathway improves overall survival and objective responses in patients with metastatic melanoma 7,8 , helped to establish a new field of ‘immune checkpoint blockade’.”
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“IHC staining with PD-1 and PD-L1 staining has been described previously 55–57 .”
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“A cardinal feature of immune checkpoint therapy is the induced durability of tumour rejection responses 2 .”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256 · cited 1×
“CTLA-4 and PD-1 are the first immune checkpoints to be characterized and clinically targeted 1–3 .”
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“CTLA-4 and PD-1 are the first immune checkpoints to be characterized and clinically targeted 1–3 .”
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381 · cited 1×
“…cancer to a -CTLA-4 monotherapy and the recent report of a noteworthy activity of a -PD-L1 antibody MDPDL3280A in patients with bladder cancer 53 , we reason that combination therapy represents a more effective approach, which is consistent with our observations of the high expression of…”
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Self-citationKaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni1009 · Cited by 1,830
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Self-citationAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437 · cited 1×
“The PD-1/PD-L1 pathway is a primary ligand–receptor coinhibitory interaction in tumours 20 .”
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329 · cited 1×
“…-PD-1 and a -CTLA-4 led to complete rejection of bladder tumours, in contrast to the inefficient monotherapies, an outcome further confirmed in the Renca model for renal cancer, which parallels preliminary results from a phase I clinical trial of combination therapy in metastatic RCC patients 14,38 .”
MOUSE CD1-SPECIFIC NK1 T CELLS: Development, Specificity, and Function
Bendelac, A., Rivera, M. N., Park, S.-H., & Roark, J. H. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.535 · Cited by 1,326
Homeostasis of Naive and Memory T Cells
Surh, C. D., & Sprent, J. (2008) · Immunity · doi:10.1016/j.immuni.2008.11.002 · Cited by 1,193 · cited 3×
“Considering the pivotal role of IL-7/IL-7R a signalling pathway in the generation and maintenance of memory T cells, in particular the long-lived T CM 34–36 , we ask if combination therapy engages IL-7-IL-7R a signalling in TILs by analyzing IL-7R a expression on CD4 þ and CD8 þ TILs (Fig.”
InfluentialDifferential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829 · cited 1×
“1), namely NKT cells 27 , which also showed natural tumour surveillance capabilities 28 .”
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 1×
“Since both a -CTLA-4 and a -PD-1 treatment increase tumour T-cell infiltration in mouse and human 22–24 , we examined the abundance of CD4 þ and CD8 þ T cells in MB49 tumours treated with a -CTLA-4, a -PD-1 or combination therapy.”
Role of NK cells in tumour growth and metastasis in beige mice
Talmadge, J. E., Meyers, K. M., Prieur, D. J., & Starkey, J. R. (1980) · Nature · doi:10.1038/284622a0 · Cited by 527 · cited 1×
“Inaddition to CD4 þ and CD8 þ T cells, NK cell activity has long been associated with the destruction of tumour cells both in vitro and in vivo 26 .”
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L., & Rosenberg, S. A. (1981) · PubMed · Cited by 523
Hammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 505
Self-citationSportès, C., Hakim, F. T., Memon, S. A., Zhang, H., Chua, K. S., Brown, M. R., Fleisher, T. A., Krumlauf, M. C., Babb, R. R., Chow, C. K., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071681 · Cited by 476 · cited 2×
“Given the dual roles of IL-7 in promoting T eff survival and expansion 40,43 as well as in suppressing T reg function 41 , further explorations of combined immune checkpoint blockade and IL-7 supplementation could potentially improve antitumour therapy, as our data suggested.”
Interleukin 7 Regulates the Survival and Generation of Memory CD4 Cells
Kondrack, R. M., Harbertson, J., Tan, J. T., McBreen, M. E., Surh, C. D., & Bradley, L. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030735 · Cited by 471
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461 · cited 2×
“…human bladder tumours and murine MB49 bladder tumours, a recent report of IFN-g upregulation in patients treated with immune checkpoint blockade 37 , and the essential role of IL-7 and IFN-g sigaling in T-cell survival and function, we reason such an interdependent loop likely exsists to…”
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
Self-citationBulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Rosenberg, S. A., Sportès, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M., Morton, K. E., Mavroukakis, S. A., Morre, M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000210386.55951.c2 · Cited by 443
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Self-citationRegulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)
Simpson, T. R., Quezada, S. A., & Allison, J. P. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.001 · Cited by 233 · cited 1×
“It might also be worthwhile to explore how IFN-g /IFN-g R1 axis interacts with Fc g RIV signalling to drive intratumoral depletion of T reg upon immune checkpoint blockade, as our current data and previous reports suggested both pathways are required in this process 47,48 .”
Self-citationPellegrini, M., Calzascia, T., Elford, A. R., Shahinian, A., Lin, A. E., Dissanayake, D., Dhanji, S., Nguyen, L. T., Gronski, M. A., Morre, M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1953 · Cited by 228 · cited 1×
“Along this line, preclinical application of IL-7 yields substantial antitumour activity in different murine tumour models by expanding effector CD4 þ and CD8 þ T cells 40–42 .”
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Tötterman, T. H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c01fcb · Cited by 198 · cited 1×
“Our results are different from a previous report 52 using MB49 tumour model where the authors observed comparable therapeutic efficacy between a -CTLA-4 monotherapy and combination therapy.”
Effects of Donor Age on Neoplastic Transformation of Adult Mouse Bladder Epithelium In Vitro
(1979) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/62.4.1017 · Cited by 179 · cited 1×
“Male mice were used throughout this study to avoid interfering gender mismatch effects on immunological responses, as MB49 was derived from a male C57BL/6 mouse 21 .”
Belyaev, N. N., Brown, D. E., Diaz, A. I. G., Rae, A. J., Jarra, W., Thompson, J., Langhorne, J., & Potocnik, A. J. (2010) · Nature Immunology · doi:10.1038/ni.1869 · Cited by 154
Oshima, S., Nakamura, T., Namiki, S., Okada, E., Tsuchiya, K., Okamoto, R., Yamazaki, M., Yokota, T., Aida, M., Yamaguchi, Y., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.14.6298-6310.2004 · Cited by 145 · cited 1×
“In human intestinal epithelial cells, IFN-g can induce IL-7 gene expression via binding of its downstream target IFN regulatory factor-1 (IRF-1) to an IFN-stimulated response element (ISRE) located in the 5 0 upstream region of the IL-7 gene 49 .”
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hammers, H. J., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Razak, A. R. A., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4504 · Cited by 139 · cited 5×
“…-PD-1 and a -CTLA-4 led to complete rejection of bladder tumours, in contrast to the inefficient monotherapies, an outcome further confirmed in the Renca model for renal cancer, which parallels preliminary results from a phase I clinical trial of combination therapy in metastatic RCC patients 14,38 .”
InfluentialSelf-citationRibas, A., Comin-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132
Perna, S. K., Pagliara, D., Mahendravada, A., Liu, H., Brenner, M. K., Savoldo, B., & Dotti, G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1016 · Cited by 128
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C., Chen, A. C., Ready, N., & Rizvi, N. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8023 · Cited by 125
IL-7 Promotes CXCR3 Ligand-Dependent T Cell Antitumor Reactivity in Lung Cancer
Andersson, Å., Yang, S.-C., Huang, M., Zhu, L., Kar, U. K., Batra, R. K., Elashoff, D., Strieter, R. M., Dubinett, S. M., & Sharma, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803340 · Cited by 106 · cited 2×
“Given the dual roles of IL-7 in promoting T eff survival and expansion 40,43 as well as in suppressing T reg function 41 , further explorations of combined immune checkpoint blockade and IL-7 supplementation could potentially improve antitumour therapy, as our data suggested.”
Heninger, A.-K., Theil, A., Wilhelm, C., Petzold, C., Huebel, N., Kretschmer, K., Bonifacio, E., & Monti, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201286 · Cited by 87
Loskog, A., Dzojic, H., Vikman, S., Ninalga, C., Essand, M., Korsgren, O., & Totterman, T. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.7200 · Cited by 77 · cited 1×
“…by performing detailed analysis of human bladder tumour samples together with preclinical studies using the murine MB49 bladder tumour model, which shares impressive similarities with human bladder cancer including cell surface markers, sensitivity to apoptosis and immunological profiles 18,19 .”
Colpitts, S. L., Dalton, N. M., & Scott, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803450 · Cited by 76 · cited 1×
“Vice versa, an early report suggests that IL-7R signalling contributes to the maintenance of IFN-g - producing Th1 effector cells during chronic L. major infection 51 .”
Wang, A., Chandran, S., Shah, S. A., Chiu, Y., Paria, B. C., Aghamolla, T., Alvarez-Downing, M. M., Lee, C.-C. R., Singh, S., Li, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004306 · Cited by 59
Walzer, T., Arpin, C., Beloeil, L., & Marvel, J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2704 · Cited by 41
Callahan, M. K., Ott, P. A., Odunsi, K. O., Bertolini, S. V., Pan, L. S., Venhaus, R. R., Karakunnel, J. J., Hodi, F. S., & Wolchok, J. D. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.tps3120 · Cited by 27 · cited 1×
“Moreover, combination therapy was initiated for patients with other advanced solid tumours including select gastrointestinal cancers, head and neck squamous cell carcinoma, and hepatocellular carcinoma 16 .”
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent
Johnson, C. B., Riesenberg, B., May, B. R., Gilreath, S. C., Li, G., Staveley-O’Carroll, K. F., Garrett-Mayer, E. S., Mehrotra, S., Cole, D. J., & Rubinstein, M. P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0087-t · Cited by 25
O’Donnell, M. A., Luo, Y., HUNTER, S. E., CHEN, X., Hayes, L. L., & Clinton, S. K. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000109751.60921.da · Cited by 20
Shi, L. Z., Kalupahana, N. S., Turnis, M. E., Neale, G. A. M., Hock, H. R., Vignali, D. A. A., & Chi, H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300950110 · Cited by 20
Self-citation
Cited by
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Self-citationRoles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616
Metadata
- Authors
- Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Nature Communications
- Published
- 2016-08-08
- Volume
- 7
- Issue
- 1
- Pages
- 12335-12335
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4979067
- OpenAlex
- W2519263052
- Cited by
- 111
- References
- 60
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 18 · 2021: 15 · 2020: 15 · 2019: 12 · 2018: 9 · 2017: 10 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (SU2C-CRI)
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer
- National Cancer Institute (R01 CA1633793, R01CA163793, CA1633793, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, anti-PD-1 therapy, combination immunotherapy, tumor-infiltrating T cells, IFN-gamma receptor, immune checkpoint blockade, antitumor immunity, tumor immunosuppression, biomarkers
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms, Female, Humans, Immunologic Memory, Interferon-gamma, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, T-Lymphocytes, Signal Transduction, Interleukin-7, Up-Regulation, Lymphocytes, Tumor-Infiltrating, Receptors, Interleukin-7, Cell Line, Tumor, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.